Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4122676 | 0.83 | CYP4F2 (0.40) | TSHRDGAT1 | |
| SCHEMBL9419471 | 0.80 | CA1 (0.41) | TSHRDGAT1 | |
| SCHEMBL15233819 | 0.80 | TSHR (0.37) | TSHRDGAT1 | |
| SCHEMBL18797459 | 0.79 | CYP4F2 (0.46) | TSHR | |
| SCHEMBL10636030 | 0.77 | TSHR (0.34) | TSHRDGAT1 | |
| SCHEMBL487136 | 0.77 | MAPT (0.46) | TSHR | |
| SCHEMBL4650865 | 0.77 | CYP4F2 (0.43) | TSHRDGAT1 | |
| SCHEMBL11215497 | 0.75 | CYP4F2 (0.46) | TSHR | |
| SCHEMBL13477323 | 0.75 | CYP4F2 (0.34) | DGAT1 | |
| SCHEMBL8986987 | 0.75 | CYP4F2 (0.46) | TSHRDGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10117946-B2 | Self-assembling ultrashort peptides modified with bioactive agents by click chemistry | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2018-11-06 | — | — | US | disclosed |
| US-20150352220-A1 | SELF-ASSEMBLING ULTRASHORT PEPTIDES MODIFIED WITH BIOACTIVE AGENTS BY CLICK CHEMISTRY | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2015-12-10 | — | — | US | disclosed |
| WO-2014104974-A2 | SELF-ASSEMBLING ULTRASHORT PEPTIDES MODIFIED WITH BIOACTIVE AGENTS BY CLICK CHEMISTRY | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2014-07-03 | — | — | WO | disclosed |
| US-8163729-B2 | Modulators of α7 nicotinic acetylcholine receptors and therapeutic uses thereof | WYETH (US) | 2012-04-24 | — | — | US | disclosed |
| EP-2323988-A1 | ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS | Wyeth LLC (US) | 2011-05-25 | — | — | EP | disclosed |
| US-20100130474-A1 | ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS | WYETH (US) | 2010-05-27 | — | — | US | disclosed |
| US-20100130474-A1 | ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS | WYETH (US) | 2010-05-27 | — | — | US | disclosed |
| US-20100029606-A1 | MODULATORS OF ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTORS AND THERAPEUTIC USES THEREOF | WYETH (US) | 2010-02-04 | — | — | US | disclosed |
| WO-2010009290-A1 | ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS | WYETH (US) | 2010-01-21 | — | — | WO | disclosed |
| WO-2010009290-A1 | ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS | WYETH (US) | 2010-01-21 | — | — | WO | disclosed |
| EP-2118067-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS | Siena Biotech S.p.A. (IT) | 2009-11-18 | — | — | EP | disclosed |
| WO-2008087529-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS | SIENA BIOTECH S.P.A. (IT) | 2008-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029606-A1 | MODULATORS OF ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTORS AND THERAPEUTIC USES THEREOF | CHRNA7, CHRNA2, CHRNA6 | TSHR 490/4885DGAT1 2691/4885 |
| US-20100130474-A1 | ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS | CHRNA7, CHRNA6, CHRNA2 | TSHR 410/4885DGAT1 1977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.